Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 12, 2000

View Archived Issues

Roche and Aventis collaborate on Herceptin/Taxotere combination research

Health Canada approves Asmanex Twisthaler for treatment of asthma

Cyclacel and CV Therapeutics join forces to screen anticancer compounds

Protegrin IB-367 enters phase II for prevention of ventilator-associated pneumonia

Amylin seeks FDA approval for Symlin as adjuvant treatment in diabetes

Efficacy/safety of Campath-1H in acute and chronic leukemias reported at ASH meeting

Early clinical results for bryostatin 1 in hematological malignancies encouraging

Myriad Genetics obtains license to cancer drug in phase II

IL-2 variant with T-cell selectivity displays antitumor activity and good tolerance in animals

Celgene and NCI sign CRADA for development of anticancer compounds

SB-222200 is a potential new tool for studies on the NK3 receptor

Phase II clinical trial of 2ME2 commences at Mayo Clinic

FDA approves new indications for Prevacid

MR-33 as a potential treatment for DIC with reduced hemorrhagic risk

EMEA hands down positive opinion for Rapamune

GSAO, a novel molecule with the potential to take on both cancer and HIV

Lundbeck's insomnia drug enters phase II

Acadia and Allergan discover novel treatment for chronic pain

Glaxo Wellcome/SmithKline Beecham merger expected to be finalized in late December

Nonpeptide cathepsin D inhibitors identified at U. of California

Novel catechol-based COMT inhibitors designed by Orion research group

Zometa now available in Canada for hypercalcemia of malignancy

Amylin patents new PEG-modified exendins, exendin agonists

Catechols and prolines under study at Merck and Cubist as antimicrobial agents

Preparation and use of nonsteroidal glucocorticoid receptor modulators described by Pfizer

New MAb prepared at CNRS useful in RCC therapy, diagnosis

Galenic formulations of antithrombotic agents for s.c. administration